


Product Data Sheet

Radotinib(IY-5511)

Cat. No.:	B5846
CAS No.:	926037-48-1
Formula:	C27H21F3N8O
M.Wt:	530.5
Synonyms:	
Target:	Apoptosis
Pathway:	Bcl-2 Family
Storage:	Store at -20°C



Solvent & Solubility

≥13.73mg/ml in DMSO with warming; insoluble in EtOH; insoluble in H2O

In Vitro

Preparing Stock Solutions	Mass		1mg	5mg	10mg
	Solvent	Concentration			
		1 mM	1.8850 mL	9.4251 mL	18.8501 mL
		5 mM	0.3770 mL	1.8850 mL	3.7700 mL
		10 mM	0.1885 mL	0.9425 mL	1.8850 mL

Please refer to the solubility information to select the appropriate solvent

Biological Activity

Shortsummary

Bcr-Abl tyrosine kinase inhibitor

IC₅₀ & Target

In Vitro

Cell Viability Assay

Cell Line: Bone marrow cells (BMCs) from patients with AML

Preparation method: The solubility of this compound in DMSO is > 26.6mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reacting conditions: 1, 10, and 100 μM, 72 h, 37 °C

	Applications:	Radotinib is an inhibitor of BCR-ABL1 tyrosine kinase and has been approved for the second-line treatment of chronic myeloid leukemia. In BMCs from patients with AML, radotinib increased cleaved caspase-3, caspase-7, and caspase-9 levels, resulting in increasing apoptosis. Radotinib also induced G0/G1 phase arrest and inhibited proliferating of BMCs from patients with AML.
In Vivo	Animal experiment	
	Dosage form:	400 mg, twice daily
	Applications:	Patients' response to radotinib is comparable to other 2nd-generation tyrosine kinase inhibitors. Radotinib is well tolerated and effective in chronic phase-chronic myeloid leukemia patients with resistance and/or intolerance to imatinib.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

- [1]. Heo S K, Noh E K, Gwon G D, et al. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors[J]. European journal of pharmacology, 2016, 789: 280-290.
- [2]. Kim S H, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors[J]. Haematologica, 2014: haematol. 2013.096776.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

